‘Sell America’ trade back in the headlines, with various reports highlighting nearly US$5tn in value erased from the S&P 500 ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

"With these costs trending so nicely downward, just what I predicted they would do, there can almost be no inflation, but ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

After some tough weeks, the Danish stock market opened poorly following the Easter holidays. The C25 index fell by 1.7% in ...

The scale of President Donald Trump’s tariffs has exceeded even the most bearish forecasts — and could impact these five ...